Vimarsana
Biggest News Aggregation in the World

Complete Enrollment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Complete Enrollment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Complete Enrollment Today - Breaking & Trending Today

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization - Vimarsana News

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- CAPR, a…

Source: biztoc.com
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates - Vimarsana News

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Enrollment Completed in CAHptain-205 Study in Pediatric Classic Congenital Adrenal Hyperplasia (CAH)Target Enrollment Completed in CAHmelia-203 Study in Adult Classic CAHCAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosci...

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne...

Alterity Therapeutics Phase 2 Data Monitoring Committee - Vimarsana News

Alterity Therapeutics Phase 2 Data Monitoring Committee

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26,...

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned - Vimarsana News

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26, 2023 -- Alterity Therapeutics , a...